Live Breaking News & Updates on Dose Discontinuation

Stay updated with breaking news from Dose discontinuation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

First Report of PhALLCON: A Phase 3 Study Comparing Ponatinib vs Imatinib in Newly Diagnosed Ph+ ALL

Expert Elias Jabbour, MD, reviews clinical data from the PhALLCON study of ponatinib vs imatinib in patients with Ph+ acute lymphocytic leukemia and considers its clinical implications. ....

Elias Jabbour , First Report , Comparing Ponatinib , Newly Diagnosed , Acute Lymphocytic Leukemia , Call Cancer , All Leukemia , Ph Positive , Oph All , Tyrosine Kinase Inhibitors , Tki Therapy , Combination Therapy , Bcr Abl , Ponatinib Dose , Ponatinib Dosing , Complete Response , Survival Data , Adverse Events , Drug Adverse Event , Mrd Negativity , Mrd Negative , Duration Of Response , Crossover Therapy , Sequencing Therapy , Event Free Survival , Efs Data ,

Brii Biosciences Announces Positive Data from a Randomized, Single-Blind Study of its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, in China

Data are consistent with the results of the global Phase 3 ACTIV-2 trial, demonstrating a favorable safety and tolerability profile in people with both severe and non-severe SARS-CoV-2 infections in China Clinical benefits were observed in efficacy indicators such as RNAconversion rate, resolutionofCOVID-19 symptoms, and riskof progressing to severe disease DURHAM, N.C. and BEIJING, June 9, 2022 /PRNewswire/ Brii Biosciences Limited("Brii Bio" or the "Company", stock code: 2137.HK) a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public health burdens, and TSB Therapeutics (Beijing) Co., Ltd. ("TSB Therapeutics"), a joint venture majority-owned by the Company, today announced,positive data from a randomized, single-blind clinical study (NCT04787211) of its long-acting COVID-19 neutralizing antibody therapy, the amubarvimab/romlusevimab combination, in China. In June 2021, in parallel with ....

United States , Nanshan Zhong , Brii Bio , Rogers Luo , Therapeutics Beijing Co Ltd , National Health Commission Of China , National Institutes Of Health , Us National Institutes Of Health , Drug Administration , Brii Biosciences Limited Bio , Columbia University , Guangzhou National Laboratory , National Medical Products Administration , Tsinghua University , Brii Biosciences Limited , National Institutes , General Manager , Greater China , Chief Executive Officer , Security Administrations , Health Commissions , Antibody Therapy , Delta Plus , National Health Commission , Treatment Guidelines , Pilot Edition ,